Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $33.00

Eton Pharmaceuticals (NASDAQ:ETON) had its target price hoisted by HC Wainwright from $17.00 to $33.00 in a research report report published on Thursday, MarketBeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q1 2025 earnings at $0.04 EPS.

Several other equities analysts also recently weighed in on the company. Craig Hallum lifted their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. B. Riley began coverage on shares of Eton Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $21.00 target price on the stock.

Eton Pharmaceuticals Stock Up 2.6 %

ETON opened at $16.67 on Thursday. Eton Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $17.00. The business has a fifty day simple moving average of $12.84 and a 200-day simple moving average of $8.25. The firm has a market cap of $434.27 million, a P/E ratio of -75.77 and a beta of 1.38.

Institutional Investors Weigh In On Eton Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals during the second quarter worth about $3,095,000. Wasatch Advisors LP acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth approximately $1,431,000. Aristides Capital LLC acquired a new position in Eton Pharmaceuticals during the 2nd quarter worth approximately $658,000. Stonepine Capital Management LLC purchased a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at approximately $362,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after purchasing an additional 41,469 shares in the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.